• Publications
  • Influence
The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
To determine the prevalence, symptom pattern and impact of the irritable bowel syndrome, across eight European countries, using a standardized methodology, the aim was to establish a standard methodology and establish a baseline for this study. Expand
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
A large number of patients with IBS have experienced abdominal swelling and/or increase in girth, which are more common in patients with constipation, especially those with delayed transit. Expand
Gut‐focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome
Background : We have previously shown that hypnotherapy alters rectal sensitivity in some patients with irritable bowel syndrome. However, this previous study used incremental volume distension of aExpand
Bran and irritable bowel syndrome: time for reappraisal
All symptoms of irritable bowel syndrome were exacerbated by bran, with bowel disturbance most often adversely affected, followed by abdominal distension and pain. Expand
The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease
The Patient Health Questionnaire 15 was modified by excluding three gastrointestinal items to create the PHQ‐12 Somatic Symptom (PHQ‐ 12 SS) scale, which measures anxiety, depression and nongastrointestinal symptoms in irritable bowel syndrome. Expand
Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
The aim of this study was to investigate the therapeutic potential of a 5‐HT3 antagonist in irritable bowel syndrome. Expand
Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome
Appropriate guidelines for clinical trials in irritable bowel syndrome are needed because of the inadequacy of previously performed trials, the use of new and more adequate patient definition, newExpand
Zamifenacin (UK‐76, 654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome
Zamifenacin is a new potent gut M3 selective muscarinic antagonist developed for possible use in irritable bowel syndrome.
Conducting multinational, cross‐cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team report
Cross‐cultural, multinational research can advance the field of functional gastrointestinal disorders (FGIDs) and make a significant contribution in areas such as epidemiology, genetics, psychosocial modulators, symptom reporting and interpretation, extra‐intestinal co‐morbidity, diagnosis and treatment, determinants of disease severity, health care utilisation, and health‐related quality of life. Expand